Semaglutide and tirzepatide

Also known as: Ozempic, Rybelsus, Wegovy (semaglutide brands) · Mounjaro, Zepbound (tirzepatide brands) · GLP-1 receptor agonist (semaglutide's drug class) · Dual GIP/GLP-1 receptor agonist (tirzepatide's drug class) · LY3298176 (tirzepatide development code) · Incretin mimetics (drug class)

Medicine

Definition

Semaglutide and tirzepatide are the two medicines that define the modern era of incretin-based therapy for type 2 diabetes and obesity. Semaglutide, developed by Novo Nordisk, is a GLP-1 (glucagon-like peptide-1) receptor agonist — a peptide that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin release, suppressing glucagon, and reducing appetite through the hypothalamus. Tirzepatide, developed by Eli Lilly and Company, is a dual GIP/GLP-1 receptor agonist — a modified GIP (glucose-dependent insulinotropic polypeptide) sequence activating both the GIP and GLP-1 receptor pathways, with greater affinity for GIP receptors, given by once-weekly subcutaneous injection. (Wikipedia — Semaglutide, Wikipedia — Tirzepatide)

Both molecules are marketed in paired brands by indication: semaglutide as Ozempic (type 2 diabetes, injectable, approved in the United States in December 2017), Rybelsus (type 2 diabetes, oral tablet, September 2019), and Wegovy (chronic weight management, June 2021, with a cardiovascular-risk expansion in March 2024); tirzepatide as Mounjaro (type 2 diabetes, May 2022) and Zepbound (chronic weight management, November 2023, with an obstructive-sleep-apnea expansion in December 2024). Global demand outstripped supply from 2022 to 2025, triggering shortages, a compounding boom and crackdown in the United States, and public-health warnings — including in the Philippines. (Wikipedia — Semaglutide, Wikipedia — Tirzepatide, Inquirer.net — Novo Nordisk to offer Wegovy in PH, Manila Bulletin — PCP warning)

Identities

Authority	Value
Wikipedia	https://en.wikipedia.org/wiki/Semaglutide ; https://en.wikipedia.org/wiki/Tirzepatide
Wikidata	Semaglutide (Q27261089); Tirzepatide (Q108324770)
DBpedia	https://dbpedia.org/page/Semaglutide
ProductOntology	N/A
Wiktionary	N/A
Library of Congress Subject Headings	N/A
MeSH	Semaglutide (D000099194); Tirzepatide (supplementary concept record C2108177)
NCBI Taxonomy	N/A
AGROVOC	N/A
Google Scholar	https://scholar.google.com/scholar?q=semaglutide+tirzepatide+Philippines
ConceptNet	N/A
OpenCyc	N/A

Also Known As

Ozempic, Rybelsus, Wegovy (semaglutide brands)
Mounjaro, Zepbound (tirzepatide brands)
GLP-1 receptor agonist (semaglutide’s drug class)
Dual GIP/GLP-1 receptor agonist (tirzepatide’s drug class)
LY3298176 (tirzepatide development code)
Incretin mimetics (drug class)

Examples and Analogies

Hormone handbrake: natural GLP-1 is released after meals and broken down within minutes; semaglutide resists that degradation, so one weekly injection holds down appetite and blood sugar continuously rather than in the body’s brief bursts. (Wikipedia — Semaglutide)
Two pedals versus one: if semaglutide presses one metabolic pedal (GLP-1), tirzepatide presses two at once (GIP and GLP-1) — the “dual agonist” design behind its larger observed weight and glucose effects. (Wikipedia — Tirzepatide)
Verified approval record: Ozempic (December 2017), Rybelsus (September 2019), and Wegovy (June 2021; cardiovascular-risk indication March 2024) for semaglutide; Mounjaro (May 13, 2022) and Zepbound (November 8, 2023; sleep-apnea indication December 2024) for tirzepatide — all US approvals. (Wikipedia — Semaglutide, Wikipedia — Tirzepatide)

Usage Scenarios

1. Type 2 Diabetes Treatment

Both drugs are prescribed for glycemic control in adults with type 2 diabetes — Ozempic and Rybelsus for semaglutide, Mounjaro for tirzepatide. In the Philippines, Ozempic was approved by the Philippine Food and Drug Administration in 2022 and retailed at ₱7,560 per pen as of June 2025, in a country the Inquirer reported has around seven million diabetes patients. (Wikipedia — Semaglutide, Inquirer.net — Novo Nordisk to offer Wegovy in PH)

2. Chronic Weight Management

Wegovy and Zepbound are the weight-management brands, paired with diet and exercise for patients with obesity or overweight with weight-related comorbidities, with reported weight reductions of 15–20 percent; Novo positioned Wegovy for the Philippine market at roughly double the price of an Ozempic pen. Off-label use of the diabetes brands for weight loss — an “artificial” driver of shortage, in Philippine reporting — emptied pharmacy shelves for diabetes patients. (Inquirer.net — Novo Nordisk to offer Wegovy in PH, Wikipedia — Semaglutide)

3. Compounding During Shortage — and Its Shutdown

While the US FDA listed semaglutide (August 2022) and tirzepatide (December 2022) as in shortage, federal law allowed 503A compounding pharmacies and 503B outsourcing facilities to make copies. The FDA’s declaration that the tirzepatide shortage was resolved as of October 2, 2024 — reconfirmed after litigation, with 503B enforcement discretion to March 19, 2025 — and its February 21, 2025 Declaratory Order on semaglutide (503A until April 22, 2025; 503B until May 22, 2025) ended routine compounding of both drugs in the United States. (National Law Review — FDA removes semaglutide from shortage list, National Law Review — Tirzepatide shortage resolved, National Law Review — Texas court ruling)

Strategies

Match the molecule to the indication: prescribers distinguish the diabetes brands from the weight-management brands of the same molecule — the Philippine market has lived with this, Wegovy being registered by the Philippine FDA as early as February 2024 while Ozempic, registered for diabetes since 2022, was the brand on shelves. (Inquirer.net — Novo Nordisk to offer Wegovy in PH)
Buy registered, cold-chain-kept products: both drugs require 2–8 °C storage; Philippine reporting stresses buying only FDA-registered stock from licensed pharmacies, since online sellers break the cold chain. (Inquirer.net — Novo Nordisk to offer Wegovy in PH, FDA — counterfeit Ozempic alert)
Watch the shortage list: US compounding legality turned on the FDA’s shortage determinations; after the 2024–2025 resolutions, compounded copies reverted to unlawful “essentially copies” of commercially available drugs. (National Law Review — Texas court ruling)
Follow the litigation docket: the compounding endgame was decided in court — the compounders’ association’s challenges to both resolutions and the denial of injunctive relief on March 5, 2025 — a reminder that drug availability is set by administrative orders tested in litigation. (National Law Review — Tirzepatide shortage resolved, National Law Review — Texas court ruling)

Security and Safety Measures

Prescription-only status and registration: in the Philippines the drugs may be sold only in Philippine FDA-registered forms, and Republic Act No. 10918 (the Philippine Pharmacy Act of 2016) reserves compounding and dispensing to duly registered and licensed pharmacists. (LawPhil — RA 10918, Philstar.com — PCP cautions public)
Professional-society warnings: the Philippine College of Physicians has warned against compounded and non-FDA-registered versions of Ozempic and Mounjaro sold online or through unverified channels. (Manila Bulletin — PCP warning, Philstar.com — PCP cautions public)
Counterfeit alerts: the US FDA has repeatedly warned about counterfeit Ozempic 1 mg pens — seized units that entered the legitimate supply chain — telling patients to obtain the drug only through state-licensed pharmacies on prescription. (FDA — counterfeit Ozempic alert)
Global falsification surveillance: the World Health Organization has sounded the alarm over falsified semaglutide since 2022, including reports implicating the Philippines. (Inquirer.net — Novo Nordisk to offer Wegovy in PH)

Historical Context

The two molecules condensed a decade of incretin science into adjacent product cycles. Novo Nordisk obtained US approval of Ozempic in December 2017 and the first oral GLP-1, Rybelsus, in September 2019; Lilly followed with Mounjaro in May 2022 and Zepbound in November 2023; Novo’s weight-management brand Wegovy, approved June 2021, became the public face of the “Ozempic era,” in which weight-loss demand overwhelmed diabetes supply. (Wikipedia — Semaglutide, Wikipedia — Tirzepatide)

The shortage years followed a documented legal arc. The FDA listed semaglutide injections as in shortage from August 2022 and tirzepatide from December 2022, and US compounders — lawfully, while the listing lasted — supplied millions of doses; Novo Nordisk’s chief executive put American users of compounded GLP-1 drugs at up to 1.5 million as of January 2026. The FDA declared the tirzepatide shortage resolved as of October 2, 2024; compounders sued, lost their bid for an injunction on March 5, 2025, and appealed, while the FDA’s February 21, 2025 Declaratory Order closed the semaglutide window. In the Philippines, the same years brought the 2022 registration of Ozempic, drugstore shortages attributed to off-label use, a black market in pens that broke the cold chain, WHO alerts on falsified product reaching the country, the February 2024 registration of Wegovy, its announced launch in late 2025, and the Philippine College of Physicians’ 2026 warning against compounded and unregistered versions of both molecules. (National Law Review — FDA removes semaglutide from shortage list, National Law Review — Tirzepatide shortage resolved, National Law Review — Texas court ruling, Wikipedia — Semaglutide, Inquirer.net — Novo Nordisk to offer Wegovy in PH, Manila Bulletin — PCP warning)

Challenges and Controversies

The Compounding Wars

Shortage-era compounding generated one of the sharpest US regulatory disputes of the decade: patients and telehealth firms defended access to copies at a fraction of brand prices, while the FDA — citing supply data showing demand was met — removed the shortage basis, and the courts let the crackdown proceed, leaving modified-strength formulations in unresolved legal territory. (National Law Review — FDA removes semaglutide from shortage list, National Law Review — Texas court ruling)

Access, Price, and Patent

At ₱7,560 per Ozempic pen in Philippine retail (June 2025) and a Wegovy price roughly double that, the drugs sit far beyond most patients’ means in a country of about seven million diabetes patients. On patents, the record is global, not Philippine: semaglutide patents expire in March 2026 in India, China, and Brazil, and in 2026 in Türkiye and Canada, while United States patents run until 2032 — the industry analysis of these expiries never mentions the Philippines, whose generic-entry timeline is undocumented. (Inquirer.net — Novo Nordisk to offer Wegovy in PH, C&EN — Looming GLP-1 patent expirations)

Off-Label Demand

The weight-loss era’s central ethical complaint — that cosmetic-adjacent demand starved medical need — was documented in Philippine reporting as an “artificial” shortage: drugstores ran short of Ozempic from 2022 largely because of off-label use, pushing diabetes patients toward the black market. (Inquirer.net — Novo Nordisk to offer Wegovy in PH)

Falsified and Compounded Products

The demand boom created a counterfeit economy: WHO has flagged falsified semaglutide since 2022 including reports implicating the Philippines; the US FDA has seized counterfeit Ozempic entering its own supply chain; and the Philippine College of Physicians has cautioned the public against unregistered, compounded Ozempic and Mounjaro. (FDA — counterfeit Ozempic alert, Inquirer.net — Novo Nordisk to offer Wegovy in PH, Philstar.com — PCP cautions public, Manila Bulletin — PCP warning)